337 related articles for article (PubMed ID: 23562162)
1. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
[TBL] [Abstract][Full Text] [Related]
2. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
[TBL] [Abstract][Full Text] [Related]
3. Effects of enzyme replacement therapy started late in a murine model of mucopolysaccharidosis type I.
Pasqualim G; Baldo G; de Carvalho TG; Tavares AM; Giugliani R; Matte U
PLoS One; 2015; 10(2):e0117271. PubMed ID: 25646802
[TBL] [Abstract][Full Text] [Related]
4. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
[TBL] [Abstract][Full Text] [Related]
5. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
6. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
Ou L; Przybilla MJ; Koniar B; Whitley CB
Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
8. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
[TBL] [Abstract][Full Text] [Related]
9. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
[TBL] [Abstract][Full Text] [Related]
10. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
[TBL] [Abstract][Full Text] [Related]
11. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
12. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
[TBL] [Abstract][Full Text] [Related]
13. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.
Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR
Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900
[TBL] [Abstract][Full Text] [Related]
14. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy in feline mucopolysaccharidosis I.
Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
[TBL] [Abstract][Full Text] [Related]
16. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
[TBL] [Abstract][Full Text] [Related]
17. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
[TBL] [Abstract][Full Text] [Related]
18. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
Di Domenico C; Di Napoli D; Gonzalez Y Reyero E; Lombardo A; Naldini L; Di Natale P
Hum Gene Ther; 2006 Nov; 17(11):1112-21. PubMed ID: 17044753
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
